Work

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Year: 2024
Type: article
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W4392180047
FWCI: 1.519
Cites: 23
Cited by: 6
Related to: 10